Developer docs
API playgroundTry for free, no card

Search company profiles

ChemPartner

Full company profile

uuid0006q79

Namestring
ChemPartner
Legal namestring
ChemPartner PharmaTech Co., Ltd.
Websiteurl
chempartner.com
Company typeenum
Public
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, drug discovery services, preclinical CRO, antibody discovery, biologics development
Industry7 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research Services (Preclinical Drug Discovery)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical research contracts spanning discovery chemistry, biologics discovery, translational biology, bioprocess development, and GLP toxicology. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

chempartner.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ChemPartner is a global contract research organization (CRO) providing integrated preclinical drug discovery and development services to pharmaceutical and biotechnology companies. The company operates across four main service categories: Discovery Chemistry (synthetic, peptide, carbohydrate, nucleic acid, PROTAC, and medicinal chemistry with AIDD), Biologics Discovery (antibody discovery/engineering, ADC development, protein production), Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, GLP toxicology), and Bioprocess Development (cell line, process development, and GMP manufacturing). Services span target identification through IND-enabling studies with delivery from eight global facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% USA FDA submission supported studies
+3 more records
Product overview1 text field

ChemPartner is a global contract research organization (CRO) offering integrated, end-to-end drug discovery and development services. The company operates across four main service categories: Discovery Chemistry (synthetic chemistry, library chemistry, peptide/carbohydrate/nucleic acid chemistry, PROTAC chemistry, medicinal chemistry, computer-aided drug design, and scale-up); Biologics Discovery (antibody discovery and engineering, B cell cloning, hybridoma, phage display, fully human mAb discovery, affinity maturation, ADC development, and protein production); Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, and GLP toxicology); and Bioprocess Development (cell line and process development, scale-up, and GMP manufacturing). The company supports small molecule, biologic, and targeted protein degradation modalities, with a focus on preclinical research from target identification through IND submission.

Product and service5 records
1Discovery Chemistry Services
2Biologics Discovery Services
3Translational Biology Services
4Bioprocess Development Services
5Computer-Aided Drug Design (AIDD)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Collaboration with Canterbury Christ Church University for the establishment of ChemPartner's first European scientific hub at Discovery Park innovation campus in Sandwich, Kent. The partnership supports preclinical and translational research operations and enables closer collaboration with UK and European partners.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Medpace is a mid-sized CRO offering full-service clinical development with growing preclinical capabilities. It is relevant as a comparably-sized, science-focused CRO pursuing an integrated sponsor-partner model similar to ChemPartner's value proposition, though primarily clinical-stage.

TypeEmerging player
Description

Sai Life Sciences is an India-based CRO offering discovery, CMC, and biologics services with growing scale. It is comparable as an emerging Asian CRO pursuing an integrated service model and competing for sponsor outsourcing of chemistry, biology, and process development work.

TypeDirect peer
Description

WuXi AppTec is the largest China-based CRO/CDMO offering end-to-end discovery, development, and manufacturing services. It is the most directly comparable peer to ChemPartner in terms of full preclinical-to-clinical integrated service model, China-based scale, and global sponsor base, though materially larger.

TypeDirect peer
Description

Tigermed is a leading Chinese clinical CRO with growing preclinical capabilities. While more clinical-focused, it is increasingly expanding into early discovery, making it a relevant China-based peer with overlap in translational biology and integrated sponsor relationships.

TypeBroad incumbent
Description

Charles River Laboratories is a global, publicly traded CRO offering discovery, safety assessment, and manufacturing services. It is a broad incumbent that competes with ChemPartner's preclinical research, ADME, and biologics service lines, with significantly larger scale and deeper Western sponsor relationships.

TypeDirect peer
Description

Pharmaron is a China-headquartered, London-listed CRO offering integrated drug discovery, preclinical, and CMC services with a comparable China-plus-Western footprint. It is one of the closest direct competitors to ChemPartner in preclinical chemistry, DMPK, and safety assessment.

TypeBroad incumbent
Description

IQVIA is a global life sciences services leader offering R&D, clinical, real-world evidence, and commercial services. While primarily clinical-focused, its R&D Solutions division overlaps with ChemPartner's preclinical offerings, and it represents a benchmark for integrated sponsor relationships.

TypeBroad incumbent
Description

Labcorp Drug Development (formerly Covance) is a large diversified CRO offering preclinical, clinical, and central laboratory services. It competes with ChemPartner in preclinical toxicology, ADME, and bioanalytical work and has substantially greater scale and Western sponsor presence.

TypeDirect peer
Description

BioDuro is a China-based CRO/CDMO offering drug discovery, development, and manufacturing services with a similar integrated service menu. It is a direct peer competing for outsourced chemistry, biology, and DMPK work from Western biotech clients.

TypeDirect peer
Description

WuXi Biologics is a leading global biologics-focused CRO/CDMO providing antibody discovery, cell line development, and GMP manufacturing. It is directly comparable to ChemPartner's Biologics Discovery and Bioprocess Development service lines, particularly around antibody engineering and ADC development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChemPartner

Contract Research Services (Preclinical Drug Discovery)chempartner.com

ChemPartner firmographics

Firmographics
Name
ChemPartner
Legal name
ChemPartner PharmaTech Co., Ltd.
Website
https://chempartner.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

ChemPartner industry classification

Industry
Product category
Contract Research Services (Preclinical Drug Discovery)
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract research services
  • Drug discovery services
  • Preclinical CRO
  • Antibody discovery
  • Biologics development

Where ChemPartner is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices8 records

Markets served

ChemPartner business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Research Services: Fee-for-service preclinical research contracts spanning discovery chemistry, biologics discovery, translational biology, bioprocess development, and GLP toxicology. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

ChemPartner product offering

Product offering

Core offering

ChemPartner is a global contract research organization (CRO) providing integrated preclinical drug discovery and development services to pharmaceutical and biotechnology companies. The company operates across four main service categories: Discovery Chemistry (synthetic, peptide, carbohydrate, nucleic acid, PROTAC, and medicinal chemistry with AIDD), Biologics Discovery (antibody discovery/engineering, ADC development, protein production), Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, GLP toxicology), and Bioprocess Development (cell line, process development, and GMP manufacturing). Services span target identification through IND-enabling studies with delivery from eight global facilities.

Product overview

ChemPartner is a global contract research organization (CRO) offering integrated, end-to-end drug discovery and development services. The company operates across four main service categories: Discovery Chemistry (synthetic chemistry, library chemistry, peptide/carbohydrate/nucleic acid chemistry, PROTAC chemistry, medicinal chemistry, computer-aided drug design, and scale-up); Biologics Discovery (antibody discovery and engineering, B cell cloning, hybridoma, phage display, fully human mAb discovery, affinity maturation, ADC development, and protein production); Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, and GLP toxicology); and Bioprocess Development (cell line and process development, scale-up, and GMP manufacturing). The company supports small molecule, biologic, and targeted protein degradation modalities, with a focus on preclinical research from target identification through IND submission.

Differentiator

Problem solved

Functional benefit

Products and services

  • Discovery Chemistry Services
  • Biologics Discovery Services
  • Translational Biology Services
  • Bioprocess Development Services
  • Computer-Aided Drug Design (AIDD)

Quantifiable outcome

  • 90% USA FDA submission supported studies
  • +3 more outcomes

Companies that use ChemPartner

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

ChemPartner technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

ChemPartner partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Canterbury Christ Church UniversitycoreStrategic or Co-development Partner · 16 April 2026Collaboration with Canterbury Christ Church University for the establishment of ChemPartner's first European scientific hub at Discovery Park innovation campus in Sandwich, Kent. The partnership supports preclinical and translational research operations and enables closer collaboration with UK and European partners.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

ChemPartner competitors and assessment

Company assessment

Emerging players

  • Medpace: Medpace is a mid-sized CRO offering full-service clinical development with growing preclinical capabilities. It is relevant as a comparably-sized, science-focused CRO pursuing an integrated sponsor-partner model similar to ChemPartner's value proposition, though primarily clinical-stage.
  • Sai Life Sciences: Sai Life Sciences is an India-based CRO offering discovery, CMC, and biologics services with growing scale. It is comparable as an emerging Asian CRO pursuing an integrated service model and competing for sponsor outsourcing of chemistry, biology, and process development work.

Direct peers

  • WuXi AppTec: WuXi AppTec is the largest China-based CRO/CDMO offering end-to-end discovery, development, and manufacturing services. It is the most directly comparable peer to ChemPartner in terms of full preclinical-to-clinical integrated service model, China-based scale, and global sponsor base, though materially larger.
  • Tigermed: Tigermed is a leading Chinese clinical CRO with growing preclinical capabilities. While more clinical-focused, it is increasingly expanding into early discovery, making it a relevant China-based peer with overlap in translational biology and integrated sponsor relationships.
  • Pharmaron: Pharmaron is a China-headquartered, London-listed CRO offering integrated drug discovery, preclinical, and CMC services with a comparable China-plus-Western footprint. It is one of the closest direct competitors to ChemPartner in preclinical chemistry, DMPK, and safety assessment.
  • BioDuro (Sundia Meditech): BioDuro is a China-based CRO/CDMO offering drug discovery, development, and manufacturing services with a similar integrated service menu. It is a direct peer competing for outsourced chemistry, biology, and DMPK work from Western biotech clients.
  • WuXi Biologics: WuXi Biologics is a leading global biologics-focused CRO/CDMO providing antibody discovery, cell line development, and GMP manufacturing. It is directly comparable to ChemPartner's Biologics Discovery and Bioprocess Development service lines, particularly around antibody engineering and ADC development.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a global, publicly traded CRO offering discovery, safety assessment, and manufacturing services. It is a broad incumbent that competes with ChemPartner's preclinical research, ADME, and biologics service lines, with significantly larger scale and deeper Western sponsor relationships.
  • IQVIA: IQVIA is a global life sciences services leader offering R&D, clinical, real-world evidence, and commercial services. While primarily clinical-focused, its R&D Solutions division overlaps with ChemPartner's preclinical offerings, and it represents a benchmark for integrated sponsor relationships.
  • Labcorp Drug Development: Labcorp Drug Development (formerly Covance) is a large diversified CRO offering preclinical, clinical, and central laboratory services. It competes with ChemPartner in preclinical toxicology, ADME, and bioanalytical work and has substantially greater scale and Western sponsor presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

ChemPartner social profiles

Digital presence

ChemPartner financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChemPartner leadership team

Management profile

Number of profiles

Profiles8 records

ChemPartner funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChemPartner M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemPartner

What does ChemPartner do?

ChemPartner is a global contract research organization (CRO) providing integrated preclinical drug discovery and development services to pharmaceutical and biotechnology companies. The company operates across four main service categories: Discovery Chemistry (synthetic, peptide, carbohydrate, nucleic acid, PROTAC, and medicinal chemistry with AIDD), Biologics Discovery (antibody discovery/engineering, ADC development, protein production), Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, GLP toxicology), and Bioprocess Development (cell line, process development, and GMP manufacturing). Services span target identification through IND-enabling studies with delivery from eight global facilities.

Is ChemPartner a public or private company?

ChemPartner is a public company. It is classified as public and is currently operating.

When was ChemPartner founded?

ChemPartner was founded in 2002. It employs 501 to 1,000 people.

Where is ChemPartner based?

ChemPartner is headquartered in Shanghai, China, in the Asia region.

How does ChemPartner make money?

One revenue line is on record: contract Research Services.

Who are ChemPartner's main competitors?

Emerging players on record are Medpace and Sai Life Sciences. Direct peers are WuXi AppTec, Tigermed, Pharmaron, BioDuro (Sundia Meditech) and WuXi Biologics. Broad incumbents are Charles River Laboratories, IQVIA and Labcorp Drug Development.

Does ChemPartner have an API?

No public API is recorded for ChemPartner.

What industry is ChemPartner in?

ChemPartner's product category is Contract Research Services (Preclinical Drug Discovery). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaChemPartner opens its first European scientific hub at Discovery ParkChemPartner, an international contract research organization founded in Shanghai in 2002, has launched its first European scientific hub at Discovery Park innovation campus in Sandwich, Kent. The facility is dedicated to preclinical and translational research, supporting drug discovery with early-stage in vitro screening, and was established in collaboration with Canterbury Christ Church University. This marks the first step in ChemPartner's broader UK and EU expansion, complementing its existing R&D center in Boston and European administrative operations in Copenhagen.PR NewswireChemPartner Expands European Presence with New Scientific Site at Discovery Park, UKChemPartner announced the expansion of its European footprint with a new preclinical and translational research hub at Discovery Park in Sandwich, Kent, UK, approximately one hour from London. The facility will support client programs from early-stage in vitro screening to advanced in vivo oncology models, featuring local study directors operating in the European time zone. This site represents the first step in a broader UK/EU expansion, with additional service lines already in development.MorningstarChemPartner Expands European Presence with New Scientific Site at Discovery Park, UKChemPartner announced the opening of a new scientific hub at Discovery Park in Sandwich, Kent, UK, marking its expansion into Europe. The facility will serve as a dedicated center for preclinical and translational research, offering services ranging from early-stage in vitro screening to advanced in vivo oncology models. The company stated this is the first step in a broader UK/EU expansion, with additional service lines already in development.PR NewswireChemPartner Unveils Updated Visual Identity and Digital Experience Reflecting Its Reputation as a Trusted Biopharma PartnerChemPartner, a global contract research organization serving the biopharmaceutical industry, announced the launch of an updated visual identity and enhanced digital experience on January 1, 2026, representing a brand evolution that clarifies its visual and verbal expression after more than two decades of drug discovery operations. The refreshed digital platform at chempartner.com highlights the company's end-to-end capabilities across discovery chemistry, biologics, DMPK, and CMC, along with real-world case studies and its team of approximately 2,000 scientists. The company is simultaneously expanding its global footprint with a recently opened Boston Center of Excellence and planned 2026 openings in the UK, Australia, and Malaysia.News-MedicalAdvancing PROTAC development through innovative preclinical model systemsThe article discusses the development of preclinical model systems for evaluating PROTACs and molecular glue degraders by ChemPartner, focusing on assays that address various steps in target protein degradation. It highlights the challenges in PROTAC development such as cell permeability and efficacy assessment, and presents ChemPartner's comprehensive platform that accelerates drug discovery and efficacy validation. The article also explores limitations of PROTACs and introduces molecular glue degraders as an alternative approach.PharmiWeb.comChina Biologics Contract Manufacturing Market Industry Trends and Forecasts Report 2025-2035, Profiles of ChemPartner Biologics, JHL Biotech, JOINN Biologics, MabPlex, Mycenax Biotech, WuXi AppTec - RChina's biologics contract manufacturing market is valued at $800 million in 2025 and is projected to grow at a 13% CAGR through 2035. The report highlights over 35 CMOs/CDMOs, with Pfizer investing $350 million in a biosimilar center in Hangzhou. It also notes a 21% CAGR in partnerships and a shift toward strategic partnerships.Business Wire BlogChina Biologics Contract Manufacturing Market Industry Trends and Forecasts Report 2025-2035, Profiles of ChemPartner Biologics, JHL Biotech, JOINN Biologics, MabPlex, Mycenax Biotech, WuXi AppTec - RChina's biologics contract manufacturing market is valued at $800 million in 2025 and is projected to grow at a 13% CAGR through 2035. The market benefits from lower costs, skilled labor, and supportive regulations, with over 35 CMOs/CDMOs operating. Big pharma investments, such as Pfizer's $350 million Hangzhou center, are expected to sustain growth.FinancialContent Business PageChina Biologics Contract Manufacturing Market Industry Trends and Forecasts Report 2025-2035, Profiles of ChemPartner Biologics, JHL Biotech, JOINN Biologics, MabPlex, Mycenax Biotech, WuXi AppTec - RChina's biologics contract manufacturing market is valued at $800 million in 2025 and is projected to grow at a 13% CAGR through 2035. The market benefits from lower costs, skilled labor, and supportive regulation, with over 35 CMOs/CDMOs operating. Pfizer invested $350 million in a biosimilar center in Hangzhou.PR NewswireChemPartner Announces U.S. Expansion with New R&D Center of Excellence in Boston, MA, Enhancing Local Biopharma PartnershipsChemPartner announced its U.S. expansion with a new R&D center in Watertown, MA, opening September 10, 2025. The 12,000-square-foot facility will offer biologics discovery, pharmacology, and DMPK services, aiming to strengthen Boston biopharma partnerships.